Ethosuximide
Zarontin (ethosuximide) is a small molecule pharmaceutical. Ethosuximide was first approved as Zarontin on 1982-01-01. It is used to treat absence epilepsy and epilepsy in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Zarontin (generic drugs available since 1982-01-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethosuximide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZARONTIN | Pfizer | N-012380 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zarontin | ANDA | 2023-06-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| absence epilepsy | HP_0011147 | D004832 | G40.A |
| epilepsy | EFO_0000474 | D004827 | G40.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | 1 | — | 1 | 2 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | 1 | 1 | — | — | 1 | |
| Extensively drug-resistant tuberculosis | D054908 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ETHOSUXIMIDE |
| INN | ethosuximide |
| Description | Ethosuximide is a dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures. It has a role as an anticonvulsant, a geroprotector and a T-type calcium channel blocker. It is a pyrrolidinone and a dicarboximide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCC1(C)CC(=O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 77-67-8 |
| RxCUI | 4135 |
| ChEMBL ID | CHEMBL696 |
| ChEBI ID | 4887 |
| PubChem CID | 3291 |
| DrugBank | DB00593 |
| UNII ID | 5SEH9X1D1D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,739 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
610 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more